PDF Cover

Miltefosine Market

The market for Miltefosine was estimated at $306 million in 2024; it is anticipated to increase to $441 million by 2030, with projections indicating growth to around $598 million by 2035.

Report ID:DS1802202
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Miltefosine
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Miltefosine Market Outlook

Revenue, 2024

$306M

Forecast, 2034

$562M

CAGR, 2025 - 2034

6.3%

The Miltefosine industry revenue is expected to be around $324.9 million in 2025 and expected to showcase growth with 6.3% CAGR between 2025 and 2034. The market continues to hold significant importance within the global anti-parasitic therapeutics landscape due to the persistent burden of neglected tropical diseases and increasing efforts toward disease elimination programs in endemic regions. Rising prevalence of visceral leishmaniasis and related parasitic infections across parts of Asia, Africa, and Latin America is supporting sustained demand for effective oral treatment options. Public health initiatives led by governments, non-governmental organizations, and international healthcare agencies are further strengthening accessibility and treatment adoption. In addition, ongoing investments in infectious disease research, improved diagnostic capabilities, and expanded pharmaceutical distribution networks are enhancing the commercial relevance of miltefosine-based therapies in developing healthcare markets.

Miltefosine is an oral alkylphosphocholine drug primarily used for the treatment of leishmaniasis, including visceral, cutaneous, and mucosal forms of the disease. The drug functions by disrupting parasite cell membrane integrity and metabolic activity, making it an effective therapeutic option against protozoal infections. Miltefosine is widely utilized in tropical disease treatment programs, hospital infectious disease departments, and public healthcare initiatives due to its oral administration advantage compared to injectable anti-parasitic therapies. Key features include broad anti-leishmanial activity, outpatient treatment suitability, and relatively simplified dosing protocols. Recent market trends include increasing development of combination therapies to reduce drug resistance risks, expansion of neglected tropical disease control programs, and growing pharmaceutical collaborations focused on improving treatment accessibility in low-resource regions. Advancements in tropical disease surveillance and international funding support are also contributing to rising demand for miltefosine-based treatment solutions.

Miltefosine market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Miltefosine Market Outlook

Market Key Insights

  • The Miltefosine market is projected to grow from $305.6 million in 2024 to $563 million in 2034. This represents a CAGR of 6.3%, reflecting rising demand across Leishmaniasis, Acanthamoeba keratitis, and Anti-Cancer Therapies.

  • Paladin Labs, Profounda Inc, Knight Therapeutics Inc are among the leading players in this market, shaping its competitive landscape.

  • U.S. and India are the top markets within the Miltefosine market and are expected to observe the growth CAGR of 4.1% to 6.0% between 2024 and 2030.

  • Emerging markets including Brazil, Nigeria and Indonesia are expected to observe highest growth with CAGR ranging between 7.2% to 8.7%.

  • Transition like Transition from Injectable Parasitic Therapies Toward Oral Miltefosine-Based Treatment Approaches has greater influence in U.S. and India market's value chain; and is expected to add $15 million of additional value to Miltefosine industry revenue by 2030.

  • The Miltefosine market is set to add $257 million between 2024 and 2034, with manufacturer targeting Specialty Clinics & Homecare Application projected to gain a larger market share.

  • With

    growing demand in antiparasitic treatments, and

    Emergence of Multidrug-Resistant Pathogens, Miltefosine market to expand 84% between 2024 and 2034.

miltefosine market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Miltefosine - Country Share Analysis

Opportunities in the Miltefosine

The growing prevalence of canine leishmaniasis is also creating new opportunities for miltefosine in veterinary healthcare applications. Veterinary clinics and animal health providers increasingly utilize oral miltefosine formulations to manage parasitic infections in dogs, particularly across Mediterranean countries, Latin America, and parts of Southern Europe where leishmaniasis remains endemic. Veterinary oral suspension and capsule formulations are expected to witness increasing demand due to easier administration and improved treatment compliance. Rising pet healthcare expenditure, growing awareness regarding zoonotic disease transmission, and expansion of companion animal treatment infrastructure are encouraging pharmaceutical companies to strengthen veterinary-focused miltefosine product development and distribution strategies.

Growth Opportunities in North America and Asia-Pacific

In North America, Miltefosine is positioned as a leading antiprotozoal medication. Rapid advancements in healthcare infrastructure, alongside high public awareness of parasitic diseases, present attractive growth opportunities in this market. Increased access to medical care and improved diagnostic procedures augment the demand for Miltefosine, particularly as treatment for Leishmaniasis and as a crucial part of anti-amoeba therapies. Nonetheless, market expansion faces barriers, such as intense competition among manufacturers and high production costs, creating a demand for economical and effective revisions in the drugs manufacturing protocol. Drivers within this region include regulatory endorsements by health bodies and increased focus on research and development activities.
Demand for Miltefosine in the Asia-Pacific region is powered by rising incidences of parasitic infections and a growing emphasis on public health initiatives. Promising opportunities reside in the development of newer applications of Miltefosine, beyond its traditional use in Leishmaniasis treatment, leveraging technological advancements in the pharmaceutical industry. Despite the opportunities, the market faces competition from traditional treatments and cheaper alternatives. Crucial market drivers include the populations exposure to infection-prone conditions, encouraging growth in Miltefosines demand, and robust government policies pushing for improved access to quality healthcare, thereby potentially increasing the regions market share for this anti-protozoal agent.

Market Dynamics and Supply Chain

01

Driver: Growing prevalence of leishmaniasis and expanding oral treatment adoption in endemic regions

The rising incidence of leishmaniasis in South Asia, East Africa, and Latin America is also a primary driver for miltefosine market growth. Urbanization, climate change, and limited vector control have also increased exposure to sandfly vectors, fueling case numbers of visceral and cutaneous leishmaniasis. Separately, miltefosine’s status as the first effective oral antileishmanial therapy has also boosted its uptake compared with traditional injectable therapies like amphotericin B or antimonials. Patients and healthcare systems in resource‑limited settings prefer oral regimens due to easier administration, improved compliance, and reduced hospitalization costs. These twin forces higher disease burden and the shift toward convenient oral treatment are also expanding miltefosine demand. Public health programs and global partnerships now prioritize accessible therapeutics, further supporting its inclusion in national treatment guidelines. Together, increased disease prevalence and growing acceptance of oral therapy elevate miltefosine’s relevance in neglected tropical disease control initiatives.
A key driver for miltefosine is also the expanding research interest in its potential applications beyond leishmaniasis, particularly in anti‑cancer therapies and free‑living amoebic infections such as Acanthamoeba keratitis. Preclinical studies suggest miltefosine’s ability to modulate cell membrane lipids, induce apoptosis, and disrupt pathogen viability offers promise in oncology and rare infectious disease contexts. This niche trend is also attracting interest from academic research institutions, pharmaceutical developers, and clinical trial sponsors aiming to leverage miltefosine’s unique mechanisms. As scientific exploration broadens, it supports potential pipeline expansion, attracting investment and reinforcing its strategic value as a multi‑purpose therapeutic agent.
02

Restraint: Emerging drug resistance and treatment efficacy decline impede market effectiveness

One of the most pressing restraints affecting miltefosine is the emergence of drug resistance among Leishmania parasites, which diminishes clinical effectiveness and undermines long‑term market demand. Studies from endemic regions such as India report increasing relapse rates and reduced susceptibility following repeated or incomplete treatment courses, making monotherapy less reliable and driving clinicians to prefer combination regimens or alternative therapies. The vulnerability of miltefosine to resistance proliferation in low‑resource settings, where patient adherence may falter, directly affects treatment outcomes and discourages broader adoption, limiting revenue growth and investment in this neglected disease segment.
03

Opportunity: Expanding Visceral Leishmaniasis Treatment Programs Across India and East Africa and Rising Combination Therapy Research Supporting Advanced Tropical Disease Treatment Applications

The expansion of government-supported visceral leishmaniasis elimination programs across India and East Africa is creating substantial opportunities for miltefosine manufacturers. Public health agencies increasingly promote oral anti-leishmanial therapies to improve treatment accessibility in remote and low-resource regions where injectable therapies remain difficult to administer. Capsule-based miltefosine formulations are expected to witness strong demand growth due to their suitability for outpatient treatment and simplified dosing management. International partnerships involving healthcare organizations, pharmaceutical suppliers, and disease control agencies are also strengthening medicine distribution networks. Increasing investments in disease surveillance and rural healthcare infrastructure continue supporting long-term market expansion across endemic regions.
Growing research into combination therapies for parasitic diseases is generating significant opportunities for miltefosine within infectious disease treatment programs. Healthcare researchers increasingly explore miltefosine combined with amphotericin B and paromomycin to improve therapeutic outcomes and reduce parasite resistance risks. Hospital infectious disease departments and tropical medicine institutes are expected to become major application areas for advanced combination treatment protocols. Latin America and parts of Africa are emerging as important growth regions due to rising focus on resistant leishmaniasis management. Pharmaceutical collaborations and nonprofit research initiatives are further accelerating clinical development activities supporting broader therapeutic adoption of combination-based miltefosine regimens.
04

Challenge: Limited access, affordability, and supply chain challenges restrict global market expansion

Another significant market restraint for miltefosine is its limited availability and affordability, especially in the low‑income regions most burdened by leishmaniasis. Supply chain inefficiencies, regulatory barriers, and inconsistent enforcement of public‑private partnership access agreements have resulted in frequent shortages, substandard products, and uneven distribution, making treatment less accessible where it is needed most. Even when provided at subsidized prices, procurement challenges and minimum order requirements can deter healthcare systems from stockpiling the drug. These access constraints suppress demand and reduce miltefosine’s potential impact on global public health efforts against neglected tropical diseases.

Supply Chain Landscape

1

Raw Material Procurement

Sigma-AldrichFisher Scientific
2

API Production

Gland Pharma Ltd.Cipla Ltd
3

Formulation & Packaging

Impressilo LifesciencesGlenmark Pharmaceuticals
4

Distribution & Sales

Novartis PharmaJohnson & Johnson
Miltefosine - Supply Chain

Use Cases of Miltefosine in Leishmaniasis & Acanthamoeba keratitis

Leishmaniasis : Miltefosine is primarily used as an oral antileishmanial therapy in the treatment of visceral, cutaneous, and mucocutaneous leishmaniasis, especially in regions where these parasitic diseases are endemic. Healthcare providers prescribe miltefosine capsules due to their convenience compared with traditional intravenous or injectable regimens. Its mechanism involves disrupting parasite cell membrane synthesis and signaling pathways, leading to decreased parasite viability. The oral route improves patient compliance and field‑based treatment feasibility in resource‑limited settings. Miltefosine’s broad activity against Leishmania species has made it a cornerstone in national leishmaniasis control programs and global health initiatives.
Acanthamoeba keratitis : In the management of Acanthamoeba keratitis, miltefosine is used as an off‑label topical or systemic therapeutic option by ophthalmologists when conventional antiseptic agents show limited efficacy. Acanthamoeba keratitis is a rare but serious corneal infection often associated with contact lens misuse or exposure to contaminated water. Miltefosine’s activity against free‑living amoebae makes it a valuable addition to complex treatment regimens, particularly in refractory or severe cases. Its inclusion supports efforts to rapidly reduce pathogen load, preserve vision, and limit the risk of corneal damage in affected patients.
Anti-Cancer Therapies : Miltefosine is being investigated in anti‑cancer therapies as an experimental agent that modulates cell membrane lipids and signaling involved in apoptosis and tumor growth. Oncology researchers and clinical investigators explore its potential in solid tumors and hematologic malignancies, often in combination with other chemotherapeutic or targeted agents. Its ability to interfere with phospholipid metabolism and induce programmed cell death presents opportunities to overcome resistance mechanisms in certain cancers. While not yet a mainstream oncology drug, ongoing studies aim to clarify dosing, efficacy, and safety profiles to expand miltefosine’s therapeutic scope beyond parasitic infections.

Impact of Industry Transitions on the Miltefosine Market

As a core segment of the Pharmaceutical industry, the Miltefosine market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Injectable Parasitic Therapies Toward Oral Miltefosine-Based Treatment Approaches and Transition from Monotherapy Strategies to Combination-Based Anti-Parasitic Treatment Protocols have redefined priorities across the Pharmaceutical sector, influencing how the Miltefosine market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Injectable Parasitic Therapies Toward Oral Miltefosine-Based Treatment Approaches

The miltefosine industry is transitioning from traditional injectable anti-parasitic treatments toward orally administered therapeutic approaches that improve treatment accessibility and patient compliance. Earlier therapies for leishmaniasis often required prolonged hospital-based intravenous administration, increasing healthcare costs and limiting treatment availability in rural endemic regions. Miltefosine introduced a more practical oral alternative, enabling outpatient treatment and reducing dependence on complex healthcare infrastructure. This transition is significantly impacting public health systems, tropical disease programs, and pharmaceutical distribution networks across Asia, Africa, and Latin America. For example, rural disease elimination initiatives increasingly utilize oral miltefosine therapies to improve treatment reach and reduce hospitalization burdens in underserved communities affected by visceral leishmaniasis.
02

Transition from Monotherapy Strategies to Combination-Based Anti-Parasitic Treatment Protocols

The market is also shifting from standalone miltefosine monotherapy toward combination-based treatment protocols designed to improve therapeutic effectiveness and minimize parasite resistance risks. Healthcare researchers and infectious disease specialists increasingly combine miltefosine with amphotericin B or paromomycin to enhance clinical outcomes for resistant and recurrent leishmaniasis cases. This transition is influencing pharmaceutical research, tropical medicine programs, and hospital infectious disease management practices worldwide. For instance, combination regimens are being increasingly adopted in endemic regions with rising concerns regarding treatment failure and drug resistance. The shift is further encouraging collaborative clinical research, expanded disease surveillance programs, and development of optimized dosing strategies for neglected tropical disease treatment applications.